Zentalis Pharmaceuticals (ZNTL) Total Liabilities (2019 - 2026)

Zentalis Pharmaceuticals has reported Total Liabilities for 8 years, with the latest figure at $70.4 million in Q1 2026.

• For the quarter ending Q1 2026, Total Liabilities fell 20.59% year-over-year to $70.4 million; the trailing twelve-month figure through Mar 2026 stood at $70.4 million (down 20.59% YoY), and the FY2025 full-year result was $72.8 million, down 21.89% from the prior year.
• Total Liabilities for Q1 2026 stood at $70.4 million, down from $72.8 million in the prior quarter.
• The five-year high for Total Liabilities was $114.3 million in Q4 2023, with the low at $70.4 million in Q1 2026.
• Average Total Liabilities over 5 years is $93.6 million, with a median of $96.3 million recorded in 2024.
• Year-over-year, Total Liabilities soared 161.42% in 2022 and dropped 29.23% in 2025.
• Tracing ZNTL's Total Liabilities over 5 years: stood at $105.3 million in 2022, then grew by 8.56% to $114.3 million in 2023, then dropped by 18.5% to $93.2 million in 2024, then fell by 21.89% to $72.8 million in 2025, then slipped by 3.27% to $70.4 million in 2026.
• The last three Total Liabilities figures came in at $70.4 million (Q1 2026), $72.8 million (Q4 2025), and $74.4 million (Q3 2025), per Business Quant data.

Peer Comparison